ERBB2 and neoplasm: Targeting TFs, therefore, represents a promising antitumor therapeutic strategy that could modulate a broader range of tumor properties and thus achieve a more robust and sustained therapeutic response in contrast to the typically limited effects observed in various kinase inhibitors, which primarily only block specific signaling pathways in tumor cells such as epidermal growth factor receptor (EGFR) inhibitor, Bcr-Abl inhibitor, and receptor tyrosine-protein kinase erbB-2 (HER2) inhibitor.